Condition (MeSH)
Leukemia, Prolymphocytic
ClinicalTrials.gov lists 208 trials for Leukemia, Prolymphocytic or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 18.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
172 of the 208 trials are tagged with Leukemia, Prolymphocytic itself; the rest are tagged with a narrower condition beneath it.
When did Leukemia, Prolymphocytic trials start? (33)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
- Unknown
Top of scale: 19
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 5 |
| 2020 | 4 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 9 |
Showing 10 of 33 earlier years.
No forecast is made for this condition: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 12 trials still running at the 2026-10-09 snapshot; registered median of 47 months across 153 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Leukemia, Prolymphocytic trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 72 |
| Phase 1/2 | 24 |
| Phase 2 | 59 |
| Phase 2/3 | 1 |
| Phase 3 | 15 |
| Not applicable | 18 |
| Observational | 18 |
| Unknown | 1 |
How many Leukemia, Prolymphocytic trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 16 |
| Active, not recruiting | 9 |
| Completed | 126 |
| Suspended | 1 |
| Terminated | 30 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Leukemia, Prolymphocytic trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 18 |
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
Which drugs are being tested for Leukemia, Prolymphocytic? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 34 |
| RITUXIMAB | 16 |
| Busulfan | 13 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 49 |
| Mofetil Mycophenolate | 25 |
| Total Body Irradiation | 22 |
| Peripheral blood stem cell transplantation | 20 |
| Cyclosporine 0.05% | 17 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Leukemia, Prolymphocytic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| 1 yr TRM | 93 | 1 |
| Death | 53 | 4 |
| Pneumonia | 37 | 7 |
| Lung Infection | 36 | 3 |
| Infection | 35 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Leukemia, Prolymphocytic? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2006 | Yes |
| Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. | Leukemia & lymphoma | 1994 | Yes |
| Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. | Leukemia & lymphoma | 2002 | No |
| CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. | Blood | 2001 | No |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.